Ordering Recommendation

Useful in distinguishing lymphoplasmacytic lymphoma (LPL) from other low-grade B-cell lymphoproliferative disorders which may be in the differential diagnosis. Use when monitoring patients with LPL diagnosis and previously identified MYD88 L265P mutation.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Whole blood or bone marrow in lavender (EDTA) or pink (K2EDTA).

Specimen Preparation

Whole Blood : Do not freeze. Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow : Do not freeze. Transport 3 mL bone marrow. (Min: 1 mL)

Storage/Transport Temperature

Whole Blood, Bone Marrow: Refrigerated

Unacceptable Conditions

Plasma, serum. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens.
Bone specimens submitted in non-EDTA decalcifier.

Remarks
Stability

Whole Blood or Bone Marrow: Refrigerated: 7 days; Frozen: Unacceptable

Methodology

Real-Time Polymerase Chain Reaction

Performed

Varies

Reported

5-10 days

Reference Interval

Interpretive Data

Refer to report.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81305

Components

Component Test Code* Component Chart Name LOINC
2009319 MYD88 Source 66746-9
2009320 MYD88 L265P Detection, Result
2009321 MYD88 L265P Detection, Quant 82140-5
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Lymphoplasmacytic lymphoma
  • Waldenstrom macroglobulinemia
MYD88 L265P Mutation Detection by PCR, Quantitative